Valeant: Another Fine Mess
This article was originally published in Scrip
Michael Pearson's "Leap Day" return to Valeant Pharmaceuticals International Inc. was supposed to be a victory for the CEO and his firm after he'd spent the past few months on sick leave recovering from a severe bout of pneumonia.
You may also be interested in...
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.
Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.